TABLE 2.
Patients continuing cenobamate at data cut‐off who discontinued their baseline concomitant ASMs
| Concomitant ASM a , n/N (%) | Patients continuing cenobamate (n = 177) |
|---|---|
| Lacosamide | 18/77 (23.4) |
| Levetiracetam | 13/64 (20.3) |
| Perampanel | 11/19 (57.9) |
| Clobazam | 8/30 (26.7) |
| Lamotrigine | 7/48 (14.6) |
| Zonisamide | 6/30 (20.0) |
| Carbamazepine | 5/16 (31.3) |
| Pregabalin | 5/11 (45.5) |
| Valproate b | 4/15 (26.7) |
| Oxcarbazepine | 4/15 (26.7) |
| Phenytoin | 4/12 (33.3) |
| Brivaracetam | 4/11 (36.4) |
| Eslicarbazepine | 3/13 (23.1) |
| Gabapentin | 2/3 (66.7) |
| Felbamate | 1/3 (33.3) |
| Phenobarbital | 1/3 (33.3) |
| Topiramate | 1/15 (7.0) |
| Clonazepam | 0/5 (0.0) |
| Clorazepate | 0/3 (0.0) |
Abbreviation: ASM, antiseizure medication.
a
Most patients were taking >1 concomitant ASM.
b
Includes valproic acid, sodium valproate, and divalproex sodium.